Submit a manuscript Sign up for article alerts Contact us Support

About Molecular Cancer

This page includes information about the aims and scope of Molecular Cancer, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.

Aims & scope

Molecular Cancer is an open access, peer-reviewed online journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.

Molecular Cancer promotes the exchange of ideas, concepts and findings in any area of cancer and related biomedical science, from a molecular point of view. Molecular Cancer is interested in articles from basic, translational and clinical research, opening new avenues for the understanding, prevention, diagnosis and treatment of cancer. Topics of interest include, but are not limited to: cell and tumor biology, angiogenesis, animal models, metastasis, cancer antigens and the immune response to them, cellular signalling and molecular biology, epidemiology, genetic and molecular profiling of cancer and molecular targets, cancer stem cells, DNA damage and repair, cell cycle, apoptosis, molecular virology and vaccine- and antibody-based cancer therapies.

Molecular Cancer provides an important forum for exciting findings in cancer-related research, presenting an unparalleled opportunity to communicate information to specialists and the public. The online appearance of Molecular Cancer allows the immediate publication of accepted articles and the presentation of large amounts of data and supplemental information to ensure that new research is disseminated as efficiently and quickly as possible to the scientific community.

Open access

All articles published by Molecular Cancer are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

Authors of articles published in Molecular Cancer are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.

For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article-processing charges

Open access publishing is not without costs. Molecular Cancer therefore levies an article-processing charge of £1325/$2215/€1600 for each article accepted for publication. If the submitting author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.

Indexing services

All articles published in Molecular Cancer are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Molecular Cancer include:

  • Biological Abstracts
  • BIOSIS
  • CAS
  • Citebase
  • Current contents
  • DOAJ
  • Embase
  • EmBiology
  • Google Scholar
  • Index Copernicus
  • MEDLINE
  • OAIster
  • PubMed
  • PubMed Central
  • Science Citation Index Expanded
  • SCImago
  • Scopus
  • SOCOLAR
  • Zetoc

The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).

The full text of all research articles published by BioMed Central is also available on SpringerLink.

Molecular Cancer is tracked by Thomson Reuters (ISI) and has an Impact Factor of 5.13.

Publication and peer review process

Criteria for publication

Molecular Cancer considers the following types of articles:

Research: comprehensive reports of data from original research, that reveal novel concepts of general importance and interest to the scientific community, with conclusions that deliver a substantial advance in the understanding of an important problem. The work should not only be of exceptional significance within its field but also of interest to researchers outside the immediate area.

Reviews: describe new developments of interdisciplinary significance or highlight unresolved questions and future directions; provide a critical but balanced view of the field. Reviews should focus on one topical aspect of a field rather than providing a comprehensive literature survey; they can be controversial, but should indicate opposing viewpoints. Although usually invited, if you are interested in submitting a review, please send an outline of your proposed review to the Molecular Cancer reviews Editor.

Commentaries: describe new developments of interdisciplinary significance, and highlight unresolved questions and future directions.

Hypotheses: ideas or critics of ideas with discussion that will deliver a substantial advance in the understanding of an important problem.

Letters to the Editor: These can take several forms. For example, a substantial critique or re-analysis of an article previously published in Molecular Cancer that highlights or discuses novel aspects of the research, a short communication containing 1-2 figures that explores new avenues or may provide evidence to support or disagree with published articles, or an article that may not cover 'standard research' but that may be relevant to readers.

Short communications: preliminary results of exceptional interest that are particularly topical and relevant, and for which fast publication is essential.

Peer review policies

Submitted manuscripts will be screened for suitability for Molecular Cancer by one of the journal's Section Editors and appropriate manuscripts will be sent for peer-review. Peer-reviewers are selected by appropriate Associate Editors. Decisions will be made based upon at least two reviewer reports.

Edited by Christophe Nicot and Alan Storey, Molecular Cancer is supported by an expert Editorial Board.

Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Molecular Cancer, a personalized section of the site.

Reprints

High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.

Supplements

Molecular Cancer will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.

Editorial policies

All manuscripts submitted to Molecular Cancer should adhere to BioMed Central's editorial policies.

Citing articles in Molecular Cancer

Articles in Molecular Cancer should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Mol Cancer [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Mol Cancer 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Why publish your article in Molecular Cancer?

High visibility

Molecular Cancer's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.

Speed of publication

Molecular Cancer offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Molecular Cancer, BioMed Central and PubMed Central and will also be included in PubMed.

Flexibility

Online publication in Molecular Cancer gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Molecular Cancer are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Molecular Cancer's pages and on the BioMed Central homepage.

In addition, articles published in Molecular Cancer may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Molecular Cancer. A list of articles recently press-released by journals published by BioMed Central is available here.

Authors of articles published in Molecular Cancer retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement).

For further information about the advantages of publishing in a journal from BioMed Central, please click here.